First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors BIOLOGICS-TARGETS & THERAPY Nguyen, K. H., Neal, J. W. 2012; 6: 337–45

View details for DOI 10.2147/BTT.S26558

View details for Web of Science ID 000214920000035